|
May 29
|
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
|
|
May 28
|
H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock
|
|
Apr 8
|
Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?
|
|
Mar 12
|
Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue?
|
|
Feb 23
|
Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts
|
|
Feb 22
|
Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now?
|
|
Feb 19
|
Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently
|
|
Jan 17
|
Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential
|
|
Jan 16
|
Roivant Sciences buys Immunovant Inc. shares and repurchases its own stock for $336.9 million each
|
|
Oct 1
|
Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?
|
|
Sep 30
|
Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy?
|
|
Sep 9
|
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
|
|
Sep 9
|
Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses
|
|
Sep 9
|
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
|
|
Sep 9
|
Roivant Provides Update on Graves’ Disease Development Program
|
|
Sep 9
|
Immunovant Provides Update on Graves’ Disease Development Program
|
|
Jul 23
|
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth
|
|
May 13
|
Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet
|
|
May 7
|
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
|
|
May 6
|
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
|